All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Saved in:
Bibliographic Details
Title: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Authors: Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Cuglievan B; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX., El Hajjar G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Duose DY; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Housto, TX., Zhang B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Housto, TX., Furudate K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Ning J; Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Xiao L; Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Mouhayar E; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX., Pinto A; Pupil Bio, Houston, TX., Bidikian A; Department of Internal Medicine, Yale School of Medicine and Yale New Haven Hospital, New Haven, CT., Thompson E; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Farhat A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., McCall D; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Tan S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Bazinet A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jun 11, pp. JCO2601159. Date of Electronic Publication: 2026 Jun 11.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42272166
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Issa+GC%22">Issa GC</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Cuglievan+B%22">Cuglievan B</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22El+Hajjar+G%22">El Hajjar G</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Jen+WY%22">Jen WY</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Bataller+A%22">Bataller A</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Short+NJ%22">Short NJ</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22DiNardo+CD%22">DiNardo CD</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Alvarado+Y%22">Alvarado Y</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Loghavi+S%22">Loghavi S</searchLink>; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Duose+DY%22">Duose DY</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Housto, TX.<br /><searchLink fieldCode="AU" term="%22Zhang+B%22">Zhang B</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Housto, TX.<br /><searchLink fieldCode="AU" term="%22Furudate+K%22">Furudate K</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Ning+J%22">Ning J</searchLink>; Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Xiao+L%22">Xiao L</searchLink>; Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Mouhayar+E%22">Mouhayar E</searchLink>; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Pinto+A%22">Pinto A</searchLink>; Pupil Bio, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Bidikian+A%22">Bidikian A</searchLink>; Department of Internal Medicine, Yale School of Medicine and Yale New Haven Hospital, New Haven, CT.<br /><searchLink fieldCode="AU" term="%22Thompson+E%22">Thompson E</searchLink>; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Daver+N%22">Daver N</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Garcia-Manero+G%22">Garcia-Manero G</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Farhat+A%22">Farhat A</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22McCall+D%22">McCall D</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Kadia+TM%22">Kadia TM</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Abbas+HA%22">Abbas HA</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Tan+S%22">Tan S</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Bazinet+A%22">Bazinet A</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Jabbour+E%22">Jabbour E</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Montalban-Bravo+G%22">Montalban-Bravo G</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Ravandi+F%22">Ravandi F</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Takahashi+K%22">Takahashi K</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Andreeff+M%22">Andreeff M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Kantarjian+HM%22">Kantarjian HM</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2026 Jun 11, pp. JCO2601159. <i>Date of Electronic Publication: </i>2026 Jun 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42272166
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO-26-01159
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: JCO2601159
    Titles:
      – TitleFull: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Issa GC
      – PersonEntity:
          Name:
            NameFull: Cuglievan B
      – PersonEntity:
          Name:
            NameFull: El Hajjar G
      – PersonEntity:
          Name:
            NameFull: Jen WY
      – PersonEntity:
          Name:
            NameFull: Bataller A
      – PersonEntity:
          Name:
            NameFull: Short NJ
      – PersonEntity:
          Name:
            NameFull: DiNardo CD
      – PersonEntity:
          Name:
            NameFull: Alvarado Y
      – PersonEntity:
          Name:
            NameFull: Loghavi S
      – PersonEntity:
          Name:
            NameFull: Duose DY
      – PersonEntity:
          Name:
            NameFull: Zhang B
      – PersonEntity:
          Name:
            NameFull: Furudate K
      – PersonEntity:
          Name:
            NameFull: Ning J
      – PersonEntity:
          Name:
            NameFull: Xiao L
      – PersonEntity:
          Name:
            NameFull: Mouhayar E
      – PersonEntity:
          Name:
            NameFull: Pinto A
      – PersonEntity:
          Name:
            NameFull: Bidikian A
      – PersonEntity:
          Name:
            NameFull: Thompson E
      – PersonEntity:
          Name:
            NameFull: Daver N
      – PersonEntity:
          Name:
            NameFull: Garcia-Manero G
      – PersonEntity:
          Name:
            NameFull: Farhat A
      – PersonEntity:
          Name:
            NameFull: McCall D
      – PersonEntity:
          Name:
            NameFull: Kadia TM
      – PersonEntity:
          Name:
            NameFull: Abbas HA
      – PersonEntity:
          Name:
            NameFull: Tan S
      – PersonEntity:
          Name:
            NameFull: Bazinet A
      – PersonEntity:
          Name:
            NameFull: Jabbour E
      – PersonEntity:
          Name:
            NameFull: Montalban-Bravo G
      – PersonEntity:
          Name:
            NameFull: Ravandi F
      – PersonEntity:
          Name:
            NameFull: Takahashi K
      – PersonEntity:
          Name:
            NameFull: Andreeff M
      – PersonEntity:
          Name:
            NameFull: Kantarjian HM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 06
              Text: 2026 Jun 11
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1